Attacking covid-19 progression using multi-drug therapy for synergetic target engagement

Mathew A. Coban, Juliet Morrison, Sushila Maharjan, David Hyram Hernandez Medina, Wanlu Li, Yu Shrike Zhang, William D. Freeman, Evette S. Radisky, Karine G. Le Roch, Carla M. Weisend, Hideki Ebihara, Thomas R. Caulfield

Research output: Contribution to journalArticlepeer-review


COVID-19 is a devastating respiratory and inflammatory illness caused by a new coronavirus that is rapidly spreading throughout the human population. Over the past 12 months, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for COVID-19, has already infected over 160 million (>20% located in United States) and killed more than 3.3 million people around the world (>20% deaths in USA). As we face one of the most challenging times in our recent history, there is an urgent need to identify drug candidates that can attack SARS-CoV-2 on multiple fronts. We have therefore initiated a computational dynamics drug pipeline using molecular modeling, structure simulation, docking and machine learning models to predict the inhibitory activity of several million compounds against two essential SARS-CoV-2 viral proteins and their host protein interactors—S/Ace2, Tmprss2, Cathepsins L and K, and Mpro—to prevent binding, membrane fusion and replication of the virus, respectively. All together, we generated an ensemble of structural conformations that increase high-quality docking outcomes to screen over >6 million compounds including all FDA-approved drugs, drugs under clinical trial (>3000) and an additional >30 million selected chemotypes from fragment libraries. Our results yielded an initial set of 350 high-value compounds from both new and FDA-approved compounds that can now be tested experimentally in appropriate biological model systems. We anticipate that our results will initiate screening campaigns and accelerate the discovery of COVID-19 treatments.

Original languageEnglish (US)
Article number787
Issue number6
StatePublished - Jun 2021


  • Bioprinting
  • Drug discovery
  • Multi-drug therapy

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology


Dive into the research topics of 'Attacking covid-19 progression using multi-drug therapy for synergetic target engagement'. Together they form a unique fingerprint.

Cite this